Difference between revisions of "Vemurafenib (Zelboraf)"
(updated content) |
|||
| Line 11: | Line 11: | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| − | == | + | ==More drug information== |
| + | *[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763 DailyMed information] | ||
*[http://www.uptodate.com/contents/vemurafenib-patient-drug-information Vemurafenib (Zelboraf) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vemurafenib-patient-drug-information Vemurafenib (Zelboraf) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/vemurafenib-patient-drug-information Vemurafenib (Zelboraf) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vemurafenib-patient-drug-information Vemurafenib (Zelboraf) patient drug information (UpToDate)]</ref> | ||
Revision as of 14:58, 16 April 2015
General information
Class/mechanism: Tyrosine kinase inhibitor of some mutated forms of BRAF serine/threonine
kinase, including BRAF V600E. Also has been observed to inhibit other tyrosine kinases such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR. Certain BRAF mutations, such as V600E, result in constitutive activation of cell proliferation pathways and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
More drug information
Also known as
PLX4032, RG7204, and RO5185426.